Product
OriCAR-017
2 clinical trials
15 indications
Indication
CancerIndication
Plasma CellIndication
NeoplasmsIndication
Hemostatic DisordersIndication
Vascular DiseasesIndication
Cardiovascular DiseasesIndication
ParaproteinemiaIndication
Protein Metabolism DisordersIndication
Hematologic DisordersIndication
Hemorrhagic DisordersIndication
Lymphoproliferative DisordersIndication
Immunoproliferative DisordersIndication
Immune System DiseasesIndication
Multiple MyelomaClinical trial
An Open Label,Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Autologous T Cell Injection Targeting GPRC5D OriCAR-017 in Patients With Relapsed and/or Refractory MultiplemyelomaStatus: , Estimated PCD: 2026-11-30
Clinical trial
A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.Status: Recruiting, Estimated PCD: 2026-12-12